Published in PLoS One on March 04, 2014
HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. Am J Physiol Renal Physiol (2014) 0.93
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol (2017) 0.84
Novel Mechanisms of Herbal Therapies for Inhibiting HMGB1 Secretion or Action. Evid Based Complement Alternat Med (2015) 0.84
Axonal amphoterin mRNA is regulated by translational control and enhances axon outgrowth. J Neurosci (2015) 0.84
Blueberry Anthocyanins-Enriched Extracts Attenuate Cyclophosphamide-Induced Cardiac Injury. PLoS One (2015) 0.81
Simvastatin Reduces Lipopolysaccharides-Accelerated Cerebral Ischemic Injury via Inhibition of Nuclear Factor-kappa B Activity. Biomol Ther (Seoul) (2015) 0.80
Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis. Int J Clin Exp Pathol (2015) 0.80
Neuroprotective effect of lentivirus mediated VEGF on rat model with cerebral ischemic injury. Int J Clin Exp Med (2015) 0.77
Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways. Oxid Med Cell Longev (2016) 0.77
Inhibiting HMGB1 with Glycyrrhizic Acid Protects Brain Injury after DAI via Its Anti-Inflammatory Effect. Mediators Inflamm (2016) 0.76
Hypothermia inhibits the propagation of acute ischemic injury by inhibiting HMGB1. Mol Brain (2016) 0.75
Dimethyl Cardamonin Exhibits Anti-inflammatory Effects via Interfering with the PI3K-PDK1-PKCα Signaling Pathway. Biomol Ther (Seoul) (2015) 0.75
High-mobility group box 1 is an important mediator of microglial activation induced by cortical spreading depression. J Cereb Blood Flow Metab (2016) 0.75
Glycyrrhizin Reduces HMGB1 and Bacterial Load in Pseudomonas aeruginosa Keratitis. Invest Ophthalmol Vis Sci (2016) 0.75
Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke. Biosci Rep (2017) 0.75
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke (1986) 8.23
The inflammatory response in myocardial infarction. Cardiovasc Res (2002) 7.92
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J (2003) 6.46
Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol (1999) 4.91
HMG-1 as a mediator of acute lung inflammation. J Immunol (2000) 4.78
Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci (1996) 3.50
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med (2009) 3.35
Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke (1997) 3.26
HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci (2006) 2.68
A signature for the HMG-1 box DNA-binding proteins. Bioessays (1993) 2.50
Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem (2004) 2.24
The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci (2008) 2.10
Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J (2007) 1.97
Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J (2009) 1.95
The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia. J Neurosci (2004) 1.85
Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock (2006) 1.80
High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem (2007) 1.77
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73
Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.72
Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke (2007) 1.67
Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res (2008) 1.54
The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. J Neuroinflammation (2010) 1.54
Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke (2004) 1.50
The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer (1997) 1.48
Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res (2005) 1.47
Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol (1995) 1.27
Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J Neurosci Res (2003) 1.22
Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res (1996) 1.19
High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab (2009) 1.16
Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J (2008) 1.14
Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther (2011) 1.08
Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther (2012) 1.05
Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin (2012) 1.04
Inhibitory effect of glycyrrhizin on lipopolysaccharide and d-galactosamine-induced mouse liver injury. Eur J Pharmacol (2007) 1.03
Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacol Sin (2011) 0.95
Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol (2012) 0.94
Role of inducible nitric oxide synthase expressed by alveolar macrophages in high mobility group box 1--induced acute lung injury. Inflamm Res (2006) 0.86